These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 1551178)

  • 1. Variability in the pharmacokinetics of epirubicin: a population analysis.
    Wade JR; Kelman AW; Kerr DJ; Robert J; Whiting B
    Cancer Chemother Pharmacol; 1992; 29(5):391-5. PubMed ID: 1551178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple-dose pharmacokinetics of epirubicin at four different dose levels: studies in patients with metastatic breast cancer.
    Jakobsen P; Steiness E; Bastholt L; Dalmark M; Lorenzen A; Petersen D; Gjedde SB; Sandberg E; Rose C; Nielsen OS
    Cancer Chemother Pharmacol; 1991; 28(1):63-8. PubMed ID: 2040035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and metabolism of epirubicin administered as i.v. bolus and 48-h infusion in patients with advanced soft-tissue sarcoma.
    Robert J; Bui NB
    Ann Oncol; 1992 Sep; 3(8):651-6. PubMed ID: 1450047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A population model of epirubicin pharmacokinetics and application to dosage guidelines.
    Ralph LD; Thomson AH; Dobbs NA; Twelves C
    Cancer Chemother Pharmacol; 2003 Jul; 52(1):34-40. PubMed ID: 12764671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epirubicin metabolism and pharmacokinetics after conventional- and high-dose intravenous administration: a cross-over study.
    Camaggi CM; Strocchi E; Carisi P; Martoni A; Melotti B; Pannuti F
    Cancer Chemother Pharmacol; 1993; 32(4):301-9. PubMed ID: 8324872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population analysis of the pharmacokinetics and the haematological toxicity of the fluorouracil-epirubicin-cyclophosphamide regimen in breast cancer patients.
    Sandström M; Lindman H; Nygren P; Johansson M; Bergh J; Karlsson MO
    Cancer Chemother Pharmacol; 2006 Aug; 58(2):143-56. PubMed ID: 16465545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pharmacokinetics of epirubicin and docetaxel in combination in rats.
    Sandström M; Simonsen LE; Freijs A; Karlsson MO
    Cancer Chemother Pharmacol; 1999; 44(6):469-74. PubMed ID: 10550567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic and pharmacodynamic studies with 4'-epi-doxorubicin in nasopharyngeal carcinoma patients.
    Hu OY; Chang SP; Jame JM; Chen KY
    Cancer Chemother Pharmacol; 1989; 24(5):332-7. PubMed ID: 2758564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: a regimen with high activity and low cardiotoxicity in advanced breast cancer.
    Conte PF; Baldini E; Gennari A; Michelotti A; Salvadori B; Tibaldi C; Danesi R; Innocenti F; Gentile A; Dell'Anna R; Biadi O; Mariani M; Del Tacca M
    J Clin Oncol; 1997 Jul; 15(7):2510-7. PubMed ID: 9215819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epirubicin. Clinical pharmacology and dose-effect relationship.
    Robert J
    Drugs; 1993; 45 Suppl 2():20-30. PubMed ID: 7693418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and toxicity of two schedules of high dose epirubicin.
    Tjuljandin SA; Doig RG; Sobol MM; Watson DM; Sheridan WP; Morstyn G; Mihaly G; Green MD
    Cancer Res; 1990 Aug; 50(16):5095-101. PubMed ID: 2379173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of relationship between systemic exposure for the component drug of the fluorouracil, epirubicin, and 4-hydroxycyclophosphamide regimen in breast cancer patients.
    Sandström M; Freijs A; Larsson R; Nygren P; Fjällskog ML; Bergh J; Karlsson MO
    J Clin Oncol; 1996 May; 14(5):1581-8. PubMed ID: 8622075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors affecting epirubicin pharmacokinetics and toxicity: evidence against using body-surface area for dose calculation.
    Gurney HP; Ackland S; Gebski V; Farrell G
    J Clin Oncol; 1998 Jul; 16(7):2299-304. PubMed ID: 9667243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative effects of paclitaxel and docetaxel on the metabolism and pharmacokinetics of epirubicin in breast cancer patients.
    Esposito M; Venturini M; Vannozzi MO; Tolino G; Lunardi G; Garrone O; Angiolini C; Viale M; Bergaglio M; Del Mastro L; Rosso R
    J Clin Oncol; 1999 Apr; 17(4):1132. PubMed ID: 10561171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epirubicin in patients with liver dysfunction: development and evaluation of a novel dose modification scheme.
    Dobbs NA; Twelves CJ; Gregory W; Cruickshanka C; Richards MA; Rubens RD
    Eur J Cancer; 2003 Mar; 39(5):580-6. PubMed ID: 12628836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epirubicin in hepatocellular carcinoma: pharmacokinetics and clinical activity.
    Dobbs NA; Twelves CJ; Rizzi P; Warwick JD; Metivier EM; Williams R; Johnson PJ
    Cancer Chemother Pharmacol; 1994; 34(5):405-10. PubMed ID: 8070007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and pharmacodynamics of combination chemotherapy with paclitaxel and epirubicin in breast cancer patients.
    Danesi R; Innocenti F; Fogli S; Gennari A; Baldini E; Di Paolo A; Salvadori B; Bocci G; Conte PF; Del Tacca M
    Br J Clin Pharmacol; 2002 May; 53(5):508-18. PubMed ID: 11994057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: a randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group.
    Bastholt L; Dalmark M; Gjedde SB; Pfeiffer P; Pedersen D; Sandberg E; Kjaer M; Mouridsen HT; Rose C; Nielsen OS; Jakobsen P; Bentzen SM
    J Clin Oncol; 1996 Apr; 14(4):1146-55. PubMed ID: 8648369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years.
    Kontny NE; Würthwein G; Joachim B; Boddy AV; Krischke M; Fuhr U; Thompson PA; Jörger M; Schellens JH; Hempel G
    Cancer Chemother Pharmacol; 2013 Mar; 71(3):749-63. PubMed ID: 23314734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of epirubicin after intravenous administration: experimental and clinical aspects.
    Dine T; Luyckx M; Brunet C; Cazin M
    Methods Find Exp Clin Pharmacol; 1991 Sep; 13(7):483-9. PubMed ID: 1784146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.